O
Omeros Corp D
D
OMER
10.110
USD
-0.21
(-2.03%)
مغلق
حجم التداول
30,732
الربح لكل سهم
-2
العائد الربحي
-
P/E
-3
حجم السوق
585,872,074
الأخبار
المقالات
العنوان: Omeros Corp
القطاع: Healthcare
الصناعة: Biotechnology
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.